Physician profile
Victoricio Singzon
NPI 1134396484
$3,986.94
in general payments reported to CMS, 2019-2025
26 companies · $876 in 2025
The $876 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $56.33 · 2021: $418 · 2022: $695 · 2023: $878 · 2024: $834 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,418 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,417.66 |
| Education | $169.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $805.64 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $525.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $468.20 | 2019-2025 | Airsupra, Brilinta, Farxiga |
| Astellas Pharma US INC | $246.48 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $229.35 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.06 | 2019-2025 | Jardiance, Tradjenta |
| E.R. Squibb & Sons, L.L.C. | $219.24 | 2022-2023 | Camzyos |
| Janssen Pharmaceuticals, INC | $178.83 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $165.94 | 2019-2025 | Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $136.24 | 2020-2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $108.99 | 2022-2025 | |
| Lilly USA, LLC | $90.65 | 2022-2023 | Mounjaro, Trulicity |
| Amgen INC. | $71.11 | 2021-2025 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $66.78 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $66.38 | 2022-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.24 | 2022-2024 | Xifaxan |
| Exact Sciences Corporation | $52.21 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $40.76 | 2022 | |
| Dexcom, INC. | $39.26 | 2023-2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $36.96 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $36.60 | 2021 | |
| Shield Therapeutics INC | $34.79 | 2023-2024 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $33.15 | 2022 | |
| Organon LLC | $14.67 | 2022 | |
| Currax Pharmaceuticals LLC | $13.99 | 2022 | |
| Allergan, INC. | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoricio Singzon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.